<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR514.html">Part 514
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 514.100  Evaluation and comment on applications.
                            </h3>
                            <p class="depth1"><em>(a)</em> After the filed application has been evaluated, the applicant  will be furnished written comment on any apparent deficiencies in the  application.</p><p class="depth1"><em>(b)</em> When the description of the methods used in, and the facilities  and controls used for, the manufacture, processing, and packing of such  new animal drug appears adequate on its face, but it is not feasible to  reach a conclusion as to the safety and effectiveness of the new animal  drug solely from consideration of this description, the applicant may be  notified that an establishment inspection is required to verify their  adequacy.</p><p class="depth1"><em>(c)</em> of the act shall be moved forward 1 day for  each day after the mailing date of the request until all of the  requested samples are received. If the samples are not received within  90 days after the request, the application will be considered withdrawn  without prejudice.</p><p class="depth1"><em>(d)</em> The information contained in an application may be insufficient  to determine whether a new animal drug is safe or effective in use if it  fails to include (among other things) a statement showing whether such  drug is to be limited to prescription sale and exempt under section  502(f) of the act from the requirement that its labeling bear adequate  directions for lay use. If such drug is to be exempt, the information  may also be insufficient if:</p><p class="depth2"><em>(1)</em> The specimen labeling proposed fails to bear adequate  information for professional use including indications, effects,  dosages, routes, methods, and frequency and duration of administration  and any relevant hazards, contraindications, side effects, and  precautions under which practitioners licensed by law to administer such  drug can use the drug for the purposes for which it is intended,  including all purposes for which it is to be advertised, or represented,  in accordance with Sec. 201.105 of this chapter, and information  concerning hazards, contraindications, side effects, and precautions  relevant with respect to any uses for which such drug is to be  prescribed.</p><p class="depth2"><em>(2)</em> The application fails to show that the labeling and advertising  of such drug will offer the drug for use only under those conditions for  which it is offered in the labeling that is part of the application.</p><p class="depth2"><em>(3)</em> The application fails to show that all labeling that furnishes  or purports to furnish information for professional use of such drug  will contain, in the same language and emphasis, the information for use  including indications, effects, dosages, routes, methods, and frequency  and duration of administration and any relevant warnings, hazards,  contraindications, side effects, and precautions, which is contained in  the labeling that is part of the application in accordance with Sec.  201.105 of this chapter.</p><p class="depth1"><em>(e)</em> The information contained in an application will be considered  insufficient to determine whether a new animal drug is safe and  effective for use when there is a refusal or failure upon written notice  to furnish inspectors authorized by the Food and Drug Administration an  adequate opportunity to inspect the facilities, controls, and records  pertinent to the application.</p><p class="depth1"><em>(f)</em> On the basis of preliminary consideration of an application or  supplemental application containing typewritten or other draft labeling  in lieu of final printed labeling, an applicant may be informed that  such application is approvable when satisfactory final printed labeling  identical in content to such draft copy is submitted.</p><p class="depth1"><em>(g)</em> When an application has been found incomplete on the basis of a  need for the kind of information described in Sec. 514.6, such  application shall be considered withdrawn without prejudice to future  filing on the date of issuance of the letter citing the inadequacies  contained in the application, unless within   30 days the sponsor chooses to avail himself of the opportunity for  hearing as prescribed by Sec. 514.111.</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
